|
IDO-PROTACs for Improving the Anti-Cancer Immune Response
NU 2020-137
INVENTORS
Derek Wainwright*
Gary Schiltz
SHORT DESCRIPTION
IDO-PROTAC that target immunosuppressive IDO activity via degradation
ABSTRACT
The median survival of primary GBM patients following aggressive surgical intervention, radiotherapy, chemotherapy, and tumor treating fields (TTF) is only ~14-16 months. Indoleamine 2,3-dioxygenase...
Published: 3/3/2026
|
Updated: 5/27/2022
|
Inventor(s):
Keywords(s): AUTM26C1, BIAUTM1, Brain cancer, Cancer/Oncology, Colon cancer, Endometrial cancer, Immunotherapy, Pancreatic cancer, Prostate cancer, PROTAC, Small molecule, Targeted protein degradation, Targeted therapy, Therapeutics
Category(s): Life Sciences > Therapeutics
|